{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:26:07Z","timestamp":1792153567592,"version":"4.4.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["445703531"],"award-info":[{"award-number":["445703531"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.kint.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:18:27Z","timestamp":1779268707000},"page":"1091-1094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond galactose-deficient IgA1: reconsidering IgA2 as a pathogenic driver in IgA nephropathy"],"prefix":"10.1016","volume":"109","author":[{"given":"Claudia","family":"Seikrit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.03.009_bib1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ckj\/sfad025","article-title":"Immune abnormalities in IgA nephropathy","volume":"16","author":"Gentile","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.03.009_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1523-1755.2005.67107.x","article-title":"IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells","volume":"67","author":"Novak","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2026.02.034","article-title":"Absence of glomerular IgA1 deposition despite overexpression of galactose-deficient IgA1 in the B cell c1galt1 knockout mouse","author":"Wu","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.009_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.009_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ki.1997.361","article-title":"Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG","volume":"52","author":"Tomana","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.009_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.03.009_bib7","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2018111156","article-title":"Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1","volume":"30","author":"Rizk","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.009_bib8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1681\/ASN.2011121160","article-title":"Development of a model of early-onset IgA nephropathy","volume":"23","author":"Okazaki","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.009_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1681\/ASN.2019040373","article-title":"Fatal attraction: immunoglobulin A and the glomerular mesangium","volume":"30","author":"Floege","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.03.009_bib10","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in Japan","volume":"63","author":"Suzuki","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.009_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/IJNRD.S120562","article-title":"IgA1 dominant subclass of latent IgA mesangial deposition in donated kidney","volume":"9","author":"Oka","year":"2016","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.kint.2026.03.009_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/bj2710285","article-title":"The structure and function of human IgA","volume":"271","author":"Kerr","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.kint.2026.03.009_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41575-021-00563-w","article-title":"Secretory IgA: controlling the gut microbiota","volume":"19","author":"Pabst","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.kint.2026.03.009_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41467-019-13992-8","article-title":"IgA subclasses have different effector functions associated with distinct glycosylation profiles","volume":"11","author":"Steffen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2026.03.009_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.ajkd.2004.10.020","article-title":"Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis","volume":"45","author":"Hisano","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.03.009_bib16","first-page":"583","article-title":"IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Sch\u00f6nlein nephritis","volume":"57","author":"Coppo","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2026.03.009_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-2249.1996.d01-859.x","article-title":"Studies of the molecular basis of IgA production, subclass regulation and class-switch recombination in IgA nephropathy patients","volume":"106","author":"Baskin","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2026.03.009_bib18","first-page":"115","article-title":"Serum levels and in vitro production of IgA subclasses in patients with primary IgA nephropathy","volume":"74","author":"van den Wall Bake","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2026.03.009_bib19","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.kint.2026.02.018","article-title":"Evidence from multicenter clinical studies and humanized mouse models indicates that glomerular mesangial IgA2 deposition contributes to the pathogenesis of IgA nephropathy","volume":"109","author":"Li","year":"2026","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:58:38Z","timestamp":1783166318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826002413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0085253826002413"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.009","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond galactose-deficient IgA1: reconsidering IgA2 as a pathogenic driver in IgA nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}